Highlights

  • Entropy Neurodynamics is developing psychedelic-derived treatments for selected medical conditions.
  • Its TRP-8803 intravenous psilocin program is being evaluated in binge eating disorder.
  • The company reported results from an oral psilocybin study involving treatment-resistant irritable bowel syndrome.
  • Clinical evidence, trial design and patient safety remain central to the development pathway.
  • Funding and regulatory requirements are continuing considerations for the research portfolio.

Entropy Neurodynamics Limited (ASX:ENP) is a clinical-stage biotechnology company developing psychedelic-derived treatments for disorders in neuropsychiatry and related conditions. Its 2026 activity has included research involving intravenous psilocin for binge eating disorder and oral psilocybin for treatment-resistant irritable bowel syndrome. These programs are at different stages of clinical evaluation, making the distinction between reported observations and established treatment outcomes important.

Binge Eating Disorder Program and TRP-8803

The company’s TRP-8803 formulation delivers psilocin intravenously, with dosing intended to be controlled during a supervised treatment session. Entropy Neurodynamics (ASX:ENP) has pursued clinical work examining this approach for binge eating disorder (BED), a condition involving recurrent episodes of uncontrolled eating. A January 2026 company disclosure discussed its clinical evaluation and the role of supportive psychotherapy during treatment.

In 2026, ASX:ENP communicated observations from an initial patient cohort and outlined continued clinical evaluation. Such early clinical findings should be distinguished from results from larger, controlled studies. Patient selection, the duration of follow-up, changes in eating behaviour and safety outcomes are relevant when interpreting the evidence.

Separate Oral Psilocybin Research in IBS

The pipeline also includes TRP-8802, an oral psilocybin formulation. In May 2026, Entropy Neurodynamics (ASX:ENP) reported findings from a Phase 2a study involving patients with treatment-resistant irritable bowel syndrome (IBS). The results related to that oral program and should not be treated as clinical evidence for intravenous TRP-8803.

IBS research involves several possible endpoints, including symptom severity, pain and patient-reported functioning. For ASX:ENP, distinguishing the oral and intravenous formulations, the conditions under study and the populations enrolled is essential to understanding the research portfolio. Findings from one indication do not automatically establish effectiveness in another.

Development Priorities and Operating Considerations

The company’s development work requires clinical trial management, specialist medical oversight and engagement with relevant regulators. Entropy Neurodynamics (ASX:ENP) must evaluate whether reported observations are repeatable, clinically meaningful and supported by an acceptable safety profile. The number of participants, the presence of a comparison group and the consistency of endpoints can materially affect the interpretation of trial results.

Research programs can also incur costs over extended periods without generating commercial product revenue. Financing requirements, study recruitment, Manufacturing arrangements and regulatory decisions therefore remain material operational considerations. None of these steps guarantees approval or commercial adoption.

Key Insights

Entropy Neurodynamics Limited (ASX:ENP) is pursuing two distinct clinical approaches, with TRP-8803 centred on intravenous psilocin and TRP-8802 involving oral psilocybin. Its 2026 disclosures describe investigational research rather than an approved therapy. The relevance of future updates will depend on the quality of clinical data, patient safety, study progress and the company’s resources to support development.